Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Development of an EGFRvIII specific recombinant antibody

(2010) Puja Gupta et al.   BMC BIOTECHNOLOGY

EGFR expression variance in paired colorectal cancer primary and metastatic tumors

(2010) Nirit Yarom et al.   CANCER BIOLOGY & THERAPY

Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer

(2010) J. R. Hecht et al.   CLINICAL CANCER RESEARCH

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities

(2009) Helmout Modjtahedi et al.   ANTI-CANCER DRUGS

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

(2009) Bart Jacobs et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

(2009) Salvatore Siena et al.   JNCI-Journal of the National Cancer Institute

Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer

(2008) Mei Wu et al.   CLINICAL THERAPEUTICS

Implications of EGFR PharmDx™ Kit for cetuximab eligibility

(2008) Christian Ensinger et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE